Palantir’s Earnings Triumph Is Clouded by a Privacy Storm and an Expensive Price Tag

Palantir just delivered the strongest quarter in its history as a public company, yet the stock took a 7% hit in a single session. The contradiction sums up the predicament facing one of the market’s most polarising names: operational brilliance collides head-on with a valuation that leaves virtually no margin for error.

Revenue surged 85% from a year earlier to $1.63 billion in the first quarter. Net profit hit roughly $871 million, translating into a margin of 53%. The strongest tailwind came from the US, where revenue climbed 104% to $1.282 billion. Chief executive Alex Karp responded by lifting the full-year revenue target to $7.66 billion, implying growth of 71% – up from the previous forecast of 61%. The second-quarter projection of $1.80 billion (an 80% increase) signals that the artificial intelligence boom is not a one-off.

Even so, the market’s reaction was one of relief, not euphoria. The shares ended Tuesday at roughly $136.83, giving back some of the year’s gains. On the German listing, Palantir closed at €116.12, leaving it 18.85% lower since January and below the 50-day moving average of €124.65. The reason is any old Wall Street hand will recite: a trailing price-to-earnings ratio above 150 and a forward multiple still near 75 mean the stock already prices in perfection.

The booking data offers one reason to hesitate. In the commercial US segment, revenues jumped 133% to $595 million, but new orders grew only 45% – a clear deceleration from the prior quarter’s pace. That deceleration reignites the debate over whether the valuation can be sustained if growth slows further. The government business, by contrast, remains on a tear: US government revenue advanced 84% to $687 million, buoyed by a large Department of Homeland Security contract and the deployment of the Maven Smart System.

Should investors sell immediately? Or is it worth buying Palantir?

Another source of tension comes from across the Atlantic. Palantir’s £330 million data project with Britain’s National Health Service has become a political lightning rod. The company recently granted its employees extensive administrative access to patient data – a move that lawmakers warn could shatter public trust. Palantir insists it acts solely as a data processor and that any misuse would be both illegal and technically impossible, but British government officials are openly discussing the possibility of terminating the contract when it comes up for renewal in 2027. A hit to the civilian health vertical would undercut one of Palantir’s most promising growth pillars beyond defence.

The defence side, meanwhile, is enjoying a moment in the sun. Karp travelled to Kiev on Tuesday to meet President Volodymyr Zelenskyy and expand the partnership that began in 2022. The focus is on the “Brave1 Dataroom” project, where Ukraine is using Palantir’s tools to intercept Russian drones and process vast quantities of reconnaissance data. Defence Minister Mykhailo Fedorov stressed the operational depth of the cooperation, and Karp described Ukraine’s innovation cycle under wartime conditions as unprecedented. The revenue from such government work contributed to the explosive US federal performance.

Profitability remains exceptional. Adjusted operating income reached $984 million, for a margin of 60%, while adjusted free cash flow came in at $925 million. Analysts have taken note: Freedom Broker raised its price target to $230, Rosenblatt to $225, and Argus initiated coverage with a “Buy” rating and a $190 target. Wedbush continues to call Palantir a primary beneficiary of the enterprise AI cycle, noting that demand for AI integration and orchestration software remains fierce.

Palantir at a turning point? This analysis reveals what investors need to know now.

But the market’s tolerance for any blemish is vanishingly thin. The next concrete test arrives with the second quarter, where the $1.80 billion revenue target will either validate the narrative or reignite the valuation debate. For a stock that trades on future expectations, even a whisper of deceleration in the US commercial order book is enough to trigger a sell-off. Palantir’s operational story is compelling – but its stock price has already written the ending.

Ad

Palantir Stock: New Analysis - 12 May

Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Palantir analysis...

en | US69608A1088 | PALANTIR’S | boerse | 69316018 |